Please login to the form below
Dainippon Sumitomo Pharma
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Dainippon Sumitomo Pharma's 2012 Japan sales performance.
BMS links up with Exscientia for $1.2bn AI drug discovery deal
Aside from its collaboration with BMS, Exscientia has a number of additional collaborations in place with other pharma companies, including Bayer, Sanofi and Dainippon Sumitomo.
A snapshot of… Exscientia
We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials. ... We’ve also signed numerous major pharma collaborations with
Myovant preps US filing for relugolix in prostate cancer
The positive trial result is also good news for Japanese drugmaker Sumitomo Dainippon, which agreed a $3bn upfront deal to acquire a 45% stake in Myovant – and control of four other
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal
Could acquire up to 11 Roivant spinouts. Japanese pharma company Sumitomo Dainippon has announced a strategic deal with Roivant Sciences, a biotech holding company headed by entrepreneur Vivek Ramaswamy, for a ... Sumitomo Dainippon's expertise in
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease
drug. The French company signed an agreement with Sumitomo Dainippon Pharma in 2017 for development rights to the drug in Asian markets including Japan, which has a slightly lower bar for
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
